{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:13:37Z","timestamp":1791810817746,"version":"4.3.4"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK040561"],"award-info":[{"award-number":["P30 DK040561"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016758","name":"Nutrition Obesity Research Center at Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016758","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Clinical Nutrition"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajcnut.2025.06.015","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:02:46Z","timestamp":1750503766000},"page":"866-885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts\u2014a report from the 25th Annual Harvard Nutrition Obesity Symposium"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-3089","authenticated-orcid":false,"given":"Gitanjali","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5082-5753","authenticated-orcid":false,"given":"Sophia L","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conner R","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takara L","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M","family":"Apovian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime P","family":"Almandoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Leggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius N","family":"Lakdawalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Socolovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Cody","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K","family":"Grinspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6676","key":"10.1016\/j.ajcnut.2025.06.015_bib1","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1126\/science.adn4691","article-title":"Obesity meets its match","volume":"382","author":"Couzin-Frankel","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib2","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/DMSO.S392684","article-title":"Novel antiobesity therapies and their different effects and safety profiles: a critical overview","volume":"16","author":"Telci Caklili","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"3","key":"10.1016\/j.ajcnut.2025.06.015_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ajcnut.2025.06.015_bib4","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7942","key":"10.1016\/j.ajcnut.2025.06.015_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-022-04505-7","article-title":"The 'breakthrough' obesity drugs that have stunned researchers","volume":"613","author":"Prillaman","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5908656","article-title":"Increasing GLP-1 Circulating levels by bariatric surgery or by GLP-1 receptor agonists therapy: why are the clinical consequences so different?","volume":"2016","author":"Amouyal","year":"2016","journal-title":"J. Diabetes Res."},{"issue":"5223","key":"10.1016\/j.ajcnut.2025.06.015_bib7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.7624769","article-title":"\u201cObese\u201d protein slims mice","volume":"269","author":"Barinaga","year":"1995","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ajcnut.2025.06.015_bib8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1056\/NEJMp038114","article-title":"To eat or not to eat\u2014how the gut talks to the brain","volume":"349","author":"Korner","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ajcnut.2025.06.015_bib9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/ng0797-218","article-title":"And finally, genes for human obesity","volume":"16","author":"Leibel","year":"1997","journal-title":"Nat. Genet."},{"issue":"Suppl 1","key":"10.1016\/j.ajcnut.2025.06.015_bib10","first-page":"S30","article-title":"Sibutramine\u2014a review of clinical efficacy","volume":"21","author":"Lean","year":"1997","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"issue":"8","key":"10.1016\/j.ajcnut.2025.06.015_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2480","article-title":"3D microscopy and deep learning reveal the heterogeneity of crown-like structure microenvironments in intact adipose tissue","volume":"7","author":"Geng","year":"2021","journal-title":"Sci. Adv."},{"issue":"17","key":"10.1016\/j.ajcnut.2025.06.015_bib12","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","article-title":"Long-term persistence of hormonal adaptations to weight loss","volume":"365","author":"Sumithran","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1172\/JCI59660","article-title":"Obesity is associated with hypothalamic injury in rodents and humans","volume":"122","author":"Thaler","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.ajcnut.2025.06.015_bib14","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.biopsych.2021.07.015","article-title":"Higher-order inputs involved in appetite control","volume":"91","author":"Azevedo","year":"2022","journal-title":"Biol. Psychiatry."},{"issue":"38","key":"10.1016\/j.ajcnut.2025.06.015_bib15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2311118120","article-title":"Hedonic eating, obesity, and addiction result from increased neuropeptide Y in the nucleus accumbens during human brain evolution","volume":"120","author":"Raghanti","year":"2023","journal-title":"Proc. Natl Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrendo.2017.122","article-title":"Current pharmacotherapy for obesity","volume":"14","author":"Srivastava","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib17","series-title":"Comparative Endocrinology for Basic and Clinical Research","article-title":"Handbook of hormones","author":"Takeuchi","year":"2021"},{"issue":"8","key":"10.1016\/j.ajcnut.2025.06.015_bib18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","volume":"20","author":"Ansari","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib20","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41574-019-0168-8","article-title":"Function and mechanisms of enteroendocrine cells and gut hormones in metabolism","volume":"15","author":"Gribble","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib21","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"24","key":"10.1016\/j.ajcnut.2025.06.015_bib22","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ajcnut.2025.06.015_bib23","first-page":"2398","article-title":"Semaglutide and heart failure with preserved ejection fraction and obesity","volume":"389","author":"Wagner","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib24","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","article-title":"Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m2: SURMOUNT-1 ambulatory blood pressure monitoring substudy","volume":"81","author":"de Lemos","year":"2024","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/ehjcvp\/pvad080","article-title":"FLOW trial stopped early due to evidence of renal protection with semaglutide","volume":"10","author":"Gragnano","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib26","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"10464","key":"10.1016\/j.ajcnut.2025.06.015_bib27","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ajcnut.2025.06.015_bib28","article-title":"Transforming steatotic liver disease management: the emerging role of GLP-1 receptor agonists, Hepatol","volume":"8","author":"Jensen","year":"2024","journal-title":"Commun."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction\u2014associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib30","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ajcnut.2025.06.015_bib31","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int. J. Obes. (Lond)."},{"issue":"7","key":"10.1016\/j.ajcnut.2025.06.015_bib32","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat. Med."},{"issue":"13","key":"10.1016\/j.ajcnut.2025.06.015_bib33","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ajcnut.2025.06.015_bib34","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/oby.23952","article-title":"Early- and later-stage persistence with antiobesity medications: a retrospective cohort study","volume":"32","author":"Gasoyan","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"10469","key":"10.1016\/j.ajcnut.2025.06.015_bib35","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","article-title":"US Obesity Forecasting Collaborators, National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990\u20132021, and forecasts up to 2050","volume":"404","year":"2024","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.ajcnut.2025.06.015_bib36","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.ajcnut.2025.06.015_bib39","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1056\/NEJMc2311840","article-title":"GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Preston","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.appet.2022.105965","article-title":"Creating the amylin story","volume":"172","author":"Lutz","year":"2022","journal-title":"Appetite"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib41","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001045","article-title":"Emerging pharmacotherapies for obesity: a systematic review","volume":"77","author":"Kokkorakis","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"10286","key":"10.1016\/j.ajcnut.2025.06.015_bib42","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","article-title":"Cagrilintide plus semaglutide for obesity management","volume":"397","author":"Becerril","year":"2021","journal-title":"Lancet."},{"issue":"10286","key":"10.1016\/j.ajcnut.2025.06.015_bib43","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"issue":"10317","key":"10.1016\/j.ajcnut.2025.06.015_bib44","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.ajcnut.2025.06.015_bib46","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib47","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/nyas.14791","article-title":"The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel","volume":"1514","author":"Reiner","year":"2022","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib49","first-page":"193","article-title":"Phase I results for AMG 133","volume":"20","author":"Greenhill","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib50","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib51","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","article-title":"Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period","volume":"10","author":"Haqq","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib52","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Cl\u00e9ment","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ajcnut.2025.06.015_bib53","doi-asserted-by":"crossref","first-page":"A669","DOI":"10.1210\/jendso\/bvab048.1367","article-title":"Effects of setmelanotide in patients with POMC, PCSK1, or LEPR heterozygous deficiency obesity in a phase 2 study","volume":"5","author":"Farooqi","year":"2021","journal-title":"J. Endocr. Soc."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.metabol.2014.07.014","article-title":"Leptin treatment: facts and expectations","volume":"64","author":"Paz-Filho","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1256514","article-title":"Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon","volume":"14","author":"Roth","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib56","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","article-title":"Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial","volume":"12","author":"Roth","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib57","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae200","article-title":"Treatment of hypothalamic obesity with GLP-1 analogs","volume":"9","author":"Dimitri","year":"2024","journal-title":"J. Endocr. Soc."},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib58","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1530\/EJE-21-0972","article-title":"Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity","volume":"186","author":"Huynh","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib59","series-title":"Saniona, Co-administration of tesofensine\/metoprolol in subjects with Prader-Willi Syndrome (PWS) (2016-003694-18)","year":"2024"},{"issue":"Suppl 1","key":"10.1016\/j.ajcnut.2025.06.015_bib61","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J. Endocr. Soc."},{"issue":"2","key":"10.1016\/j.ajcnut.2025.06.015_bib60","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00223-023-01150-8","article-title":"Narrative review of effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity","volume":"114","author":"Herrou","year":"2024","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"10.1016\/j.ajcnut.2025.06.015_bib62","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3803\/EnM.2023.1673","article-title":"New insights into calorie restriction induced bone loss, Endocrinol","volume":"38","author":"Liu","year":"2023","journal-title":"Metab. (Seoul)."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib63","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/1785321","article-title":"Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"2024","author":"Li","year":"2024","journal-title":"Int. J. Endocrinol."},{"issue":"11","key":"10.1016\/j.ajcnut.2025.06.015_bib64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40266-024-01150-9","article-title":"Pharmacological treatment of obesity in older adults","volume":"41","author":"\u017di\u017eka","year":"2024","journal-title":"Drugs Aging"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102533","article-title":"Obesity-induced neuronal senescence: unraveling the pathophysiological links","volume":"101","author":"Ghosh","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","article-title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways","volume":"22","author":"Fontanella","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib67","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimer\u2019s Dement. (N Y)."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib68","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib69","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3389\/fphar.2020.01270","article-title":"Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function","volume":"11","author":"Kim","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib70","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0405","article-title":"The emerging role of glucagon-like peptide 1 in binge eating","volume":"262","author":"Balantekin","year":"2024","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib71","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study","volume":"7","author":"Richards","year":"2023","journal-title":"Obes. Pillars."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib72","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.physbeh.2016.12.034","article-title":"Systemic administration of anorexic gut peptide hormones impairs hedonic-driven sucrose consumption in mice","volume":"171","author":"Yamaguchi","year":"2017","journal-title":"Physiol. Behav."},{"issue":"8","key":"10.1016\/j.ajcnut.2025.06.015_bib73","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaa093","article-title":"A role for GLP-1 in treating hyperphagia and obesity","volume":"161","author":"Grill","year":"2020","journal-title":"Endocrinology"},{"issue":"8","key":"10.1016\/j.ajcnut.2025.06.015_bib74","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can. J. Anaesth."},{"issue":"18","key":"10.1016\/j.ajcnut.2025.06.015_bib75","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ajcnut.2025.06.015_bib76","article-title":"Anesthesia considerations for a patient on semaglutide and delayed gastric emptying","volume":"15","author":"Fujino","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.ajcnut.2025.06.015_bib77","doi-asserted-by":"crossref","first-page":"554","DOI":"10.14309\/ajg.0000000000002969","article-title":"Glucagon-like peptide receptor agonists use before endoscopy is associated with low retained gastric contents: a multicenter cross-sectional analysis","volume":"120","author":"Phan","year":"2025","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.ajcnut.2025.06.015_bib78","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/s41386-020-00950-y","article-title":"Addiction as a brain disease revised: why it still matters, and the need for consilience","volume":"46","author":"Heilig","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMra1511480","article-title":"Neurobiologic advances from the brain disease model of addiction","volume":"374","author":"Volkow","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5335","key":"10.1016\/j.ajcnut.2025.06.015_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.278.5335.45","article-title":"Addiction is a brain disease, and it matters","volume":"278","author":"Leshner","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib81","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pharmrev.120.000083","article-title":"Drug addiction: hyperkatifeia\/negative reinforcement as a framework for medications development","volume":"73","author":"Koob","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.ajcnut.2025.06.015_bib82","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1038\/npp.2016.269","article-title":"Pathological overeating: emerging evidence for a compulsivity construct","volume":"42","author":"Moore","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib83","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn.2017.130","article-title":"The dopamine motive system: implications for drug and food addiction","volume":"18","author":"Volkow","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib84","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/bph.15682","article-title":"Glucagon-like peptide-1 (GLP-1) signalling in the brain: from neural circuits and metabolism to therapeutics","volume":"179","author":"Kabahizi","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110303","article-title":"The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review","volume":"110","author":"Guerrero-Hreins","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"issue":"7","key":"10.1016\/j.ajcnut.2025.06.015_bib86","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biom14070872","article-title":"Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration","volume":"14","author":"Kopp","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib88","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2020","journal-title":"Front. Behav. Neurosci."},{"issue":"9","key":"10.1016\/j.ajcnut.2025.06.015_bib89","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/dom.12506","article-title":"Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans","volume":"17","author":"van Bloemendaal","year":"2015","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.ajcnut.2025.06.015_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib93","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib94","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol. Behav."},{"issue":"19","key":"10.1016\/j.ajcnut.2025.06.015_bib95","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"2023","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib97","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib99","doi-asserted-by":"crossref","first-page":"23m15068","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J. Clin. Psychiatry."},{"issue":"5","key":"10.1016\/j.ajcnut.2025.06.015_bib100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib101","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J. Stud. Alcohol. Drugs."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib102","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib103","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib104","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review\u2014Glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.ajcnut.2025.06.015_bib106","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib107","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155577","article-title":"Interplay of skeletal muscle and adipose tissue: sarcopenic obesity","volume":"144","author":"Park","year":"2023","journal-title":"Metabolism"},{"issue":"13","key":"10.1016\/j.ajcnut.2025.06.015_bib109","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMcibr2003528","article-title":"Muscle atrophy and the sestrins","volume":"383","author":"Martyn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6628","key":"10.1016\/j.ajcnut.2025.06.015_bib110","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.ajcnut.2025.06.015_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdnut.2024.104486","article-title":"Sculpting success: the importance of diet and physical activity to support skeletal muscle health during weight loss with new generation antiobesity medications","volume":"8","author":"Grosicki","year":"2024","journal-title":"Curr. Dev. Nutr."},{"issue":"18","key":"10.1016\/j.ajcnut.2025.06.015_bib114","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ajcnut.2025.06.015_bib115","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jama.2020.14590","article-title":"Trends in obesity prevalence by race and Hispanic origin-1999\u20132000 to 2017\u20132018","volume":"324","author":"Ogden","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib116","first-page":"1","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017\u20132018","volume":"360","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"issue":"27","key":"10.1016\/j.ajcnut.2025.06.015_bib117","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021016","article-title":"The association of obesity with health insurance coverage and demographic characteristics: a statewide cross-sectional study","volume":"99","author":"Mylona","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib118","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.1398","article-title":"Disparities in health care spending and utilization among Black and White medicaid enrollees","volume":"3","author":"Wallace","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"2","key":"10.1016\/j.ajcnut.2025.06.015_bib119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jama.289.2.187","article-title":"Years of life lost due to obesity","volume":"289","author":"Fontaine","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.ajcnut.2025.06.015_bib120","article-title":"Benefits of medicare coverage for weight loss drugs","author":"Sexton Ward","year":"2023","journal-title":"Schaeffer Center White Paper Series"},{"issue":"5 Pt 2","key":"10.1016\/j.ajcnut.2025.06.015_bib121","first-page":"III152","article-title":"Hypertension and the department of health and human services","volume":"4","author":"Rubin","year":"1982","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib122","first-page":"CD006743","article-title":"Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event","volume":"7","author":"Perez","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib123","first-page":"CD003825","article-title":"Blood pressure lowering efficacy of loop diuretics for primary hypertension","volume":"4","author":"Musini","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ajcnut.2025.06.015_bib124","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"1","author":"Xue","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib125","article-title":"A new model for pricing drugs of uncertain efficacy","volume":"4","author":"Goldman","year":"2018","journal-title":"NEJM Catalyst"},{"issue":"25 Pt B","key":"10.1016\/j.ajcnut.2025.06.015_bib126","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.jacc.2013.11.004","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"63","author":"Jensen","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ajcnut.2025.06.015_bib127","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ajcnut.2025.06.015_bib128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am. J. Clin. Nutr."},{"issue":"Suppl 4","key":"10.1016\/j.ajcnut.2025.06.015_bib129","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1542\/peds.2007-2329C","article-title":"Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report","volume":"120","author":"Barlow","year":"2007","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib130","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/NMC.0000000000000920","article-title":"American Academy of Pediatrics issues its first guidance on childhood obesity","volume":"48","author":"Beal","year":"2023","journal-title":"MCN Am. J. Matern. Child Nurs."},{"issue":"2","key":"10.1016\/j.ajcnut.2025.06.015_bib131","article-title":"Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity","volume":"151","author":"Hampl","year":"2023","journal-title":"Pediatrics"},{"issue":"22","key":"10.1016\/j.ajcnut.2025.06.015_bib132","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib133","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/dom.13910","article-title":"A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine\/topiramate in adolescents with obesity","volume":"22","author":"Hsia","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.ajcnut.2025.06.015_bib134","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200014","article-title":"Phentermine\/topiramate for the treatment of adolescent obesity","volume":"1","author":"Kelly","year":"2022","journal-title":"NEJM Evid"},{"issue":"24","key":"10.1016\/j.ajcnut.2025.06.015_bib135","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib136","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13679-023-00534-z","article-title":"The role of lifestyle modification with second-generation antiobesity medications: comparisons, questions, and clinical opportunities","volume":"12","author":"Wadden","year":"2023","journal-title":"Curr. Obes. Rep."},{"issue":"4","key":"10.1016\/j.ajcnut.2025.06.015_bib137","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.2337\/dc13-2575","article-title":"Use of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six cases","volume":"37","author":"Fintini","year":"2014","journal-title":"Diabetes Care"}],"container-title":["The American Journal of Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002916525003375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002916525003375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T14:34:03Z","timestamp":1756823643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002916525003375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0002916525003375"],"URL":"https:\/\/doi.org\/10.1016\/j.ajcnut.2025.06.015","relation":{},"ISSN":["0002-9165"],"issn-type":[{"value":"0002-9165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel strategies for medical management of obesity: mechanisms, clinical implications, and societal impacts\u2014a report from the 25th Annual Harvard Nutrition Obesity Symposium","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajcnut.2025.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Nutrition.","name":"copyright","label":"Copyright"}]}}